Stemline Therapeutics (NASDAQ:STML) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, January 10th.
Several other research analysts have also commented on STML. HC Wainwright restated a “buy” rating and set a $34.00 price target on shares of Stemline Therapeutics in a research report on Tuesday, September 12th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. ValuEngine upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Finally, Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $33.75.
Stemline Therapeutics (STML) opened at $15.27 on Wednesday. Stemline Therapeutics has a 52-week low of $6.00 and a 52-week high of $17.40.
Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.30 million. analysts predict that Stemline Therapeutics will post -2.68 EPS for the current fiscal year.
In other Stemline Therapeutics news, COO Kenneth Hoberman sold 11,943 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.18, for a total value of $169,351.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Gionco sold 4,250 shares of the firm’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total value of $57,077.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,216 shares of company stock valued at $591,925. 15.70% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Voya Investment Management LLC acquired a new stake in shares of Stemline Therapeutics during the second quarter worth about $102,000. Nationwide Fund Advisors increased its position in shares of Stemline Therapeutics by 7.2% during the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 855 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Stemline Therapeutics during the second quarter worth about $147,000. Alliancebernstein L.P. acquired a new stake in shares of Stemline Therapeutics during the second quarter worth about $178,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Stemline Therapeutics by 40.1% during the second quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 5,522 shares in the last quarter. Institutional investors and hedge funds own 43.87% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “BidaskClub Lowers Stemline Therapeutics (STML) to Hold” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/06/bidaskclub-downgrades-stemline-therapeutics-stml-to-hold.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.